CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Deferred Tax Assets / Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Deferred Tax Assets / Liabilities | ₹-403 Cr | ₹-293 Cr | ₹-205 Cr | ₹-18 Cr | ₹125 Cr |
What is the latest Deferred Tax Assets / Liabilities ratio of CIPLA ?
Year | Deferred Tax Assets / Liabilities |
---|---|
Mar2024 | ₹-403 Cr |
Mar2023 | ₹-293 Cr |
Mar2022 | ₹-205 Cr |
Mar2021 | ₹-18 Cr |
Mar2020 | ₹125 Cr |
How is Deferred Tax Assets / Liabilities of CIPLA Trending?
Years | Deferred Tax Assets / Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹-403 Cr | Negative | |
Mar2023 | ₹-293 Cr | Negative | |
Mar2022 | ₹-205 Cr | Negative | |
Mar2021 | ₹-18 Cr | Negative | |
Mar2020 | ₹125 Cr | - |
Compare Deferred Tax Assets / Liabilities of peers of CIPLA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
CIPLA | ₹128,549.7 Cr | 0.5% | -1.7% | 29.4% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹434,604.0 Cr | 0.1% | -4% | 52.9% | Stock Analytics | |
DIVIS LABORATORIES | ₹157,639.0 Cr | 0.7% | -0% | 70.9% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹106,956.0 Cr | 1.1% | -2.6% | 19.2% | Stock Analytics | |
MANKIND PHARMA | ₹106,527.0 Cr | -2.8% | -0.7% | 52% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹97,468.9 Cr | -3.6% | -8.4% | 62.9% | Stock Analytics |
CIPLA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
CIPLA | 0.5% |
-1.7% |
29.4% |
SENSEX | -0.3% |
-2.4% |
22.4% |
You may also like the below Video Courses